Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells

Cancer Research

Volumn 58, Issue 4, 1998, Pages 801-807

  Lamm, Gábor M ^a   Christofori, Gerhard ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; ETOPOSIDE; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT SOMATOMEDIN B; RECOMBINANT SOMATOMEDIN C; STAUROSPORINE; VINCRISTINE;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; DRUG SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; INSULIN-LIKE GROWTH FACTOR II; INSULINOMA; MICE; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0032519539     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Souhami, R. Cancer therapy, cell cycle control and cell death. In: N. S. B. Thomas (ed.), Apoptosis and Cell Cycle Control in Cancer, pp. 149-160. Oxford: BIOS Scientific Publishers, Ltd., 1996.
2. Fischer, D. E. Apoptosis in cancer therapy. Cell, 78: 539-542, 1994.
3. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2: 275-280, 1990.
4. Dive, C., and Hickman, J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer, 64: 192-196, 1991.
5. Chinnaiyan, A. M., and Dixit, V. M. The cell death machine. Curr. Biol., 6: 555-562, 1996.
6. White, E. Life, death, and the pursuit of apoptosis. Genes Dev., 10: 1-15, 1996.
7. Reed, J. C. Double identity for proteins of the Bcl-2 family. Nature (Lond.), 387: 773-776, 1997.
8. Baserga, R. Oncogenes and the strategy of growth factors. Cell, 79: 927-930, 1994.
9. Collins, M. K. L., Perkins, G. R., Rodriquez-Tarduchy, G., Nieto, M. A., and López-Rivas, A. Growth factors as survival factors: regulation of apoptosis. BioEssays, 16: 133-138, 1993.
10. Baserga, R., Hongo, A., Rubini, M., Prisco, M., and Valentinis, B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta, 1332: F105-F126, 1997.
11. LeRoith, D. Insulin-like Growth Factors: Molecular and Cellular Aspects. Boca Raton: CRC Press, 1991.
12. Schofield, P. N. The insulin-like growth factors: structure and biological function. Oxford: Oxford University Press, 1992.
13. Rininsland, F., Johnson, T. R., Chernicky, C. L., Schulze, E., Burfeind, P., and Ilan, J. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc. Natl. Acad. Sci. USA, 94: 5854-5859, 1997.
14. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. c-myc-induced apoptosis in fibroblasts is inhibited by specific cylokines. EMBO J., 13: 3286-3295, 1994.
15. Sell, C., Baserga, R., and Rubin, R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res., 55: 303-306, 1995.
16. Resnicoff, M., Abraham, D., Yutenawiboonchai, W., Rotman, H. L., Kajstura, J., Rubin, R., Zoltick, P., and Baserga, R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55: 2463-2469, 1995.
17. Hanahan, D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (Lond.), 315: 115-121, 1985.
18. Teitelman, G., Alpert, S., and Hanahan, D. Proliferation, senescence, and neoplastic progression of β cells in hyperplastic pancreatic islets. Cell, 52: 97-105, 1988.
19. Christofori, G., Naik, P., and Hanahan, D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature (Lond.), 369: 414-418, 1994.
20. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (Lond.), 339: 58-61, 1989.
21. Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H., and Christofori, G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (Lond.), in press, 1998.
22. Naik, P., Christofori, G., and Hanahan, D. Insulin-like growth factor II is focally upregulated and functionally involved as a co-factor in oncogone-induced tumorigenesis. Cold Spring Harbor Symp. Quant. Biol., LIX: 459-470, 1994.
23. White, E., Cipriani, R., Sabbatini, P., and Denton, A. Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J Virol., 65: 2968-2978, 1991.
24. White, E., and Cipriani, R. Role of adenovirus E1B proteins in transformation: altered organization of intermediate filaments in transformed cells that express the 19-kilodalton protein. Mol. Cell. Biol., 10: 120-130, 1990.
25. Kato, H., Faria, T. N., Stannard, B., Roberts, C. T., Jr., and LeRoith, D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. J. Biol. Chem., 268: 2655-2661, 1993.
26. Martin-Zanca, D., Oskam, R., Mitra, G., Copeland, T., and Barbacid, M. Molecular and biochemical characterization of the human trk proto-oncogene. Mol. Cell. Biol., 9: 24-33, 1989.
27. Efrat, S., Linde, S., Kofod, H., Spector, D., Delannoy, M., Grant, S., Hanahan, D., and Baekkeskov, S. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc. Natl. Acad. Sci. USA, 85: 9037-9041, 1988.
28. Radvanyi, F., Christgau, S., Baekkeskov, S., Jolicoeur, C., and Hanahan, D. Pancreatic β cells cultured from individual preneoplastic foci in a multistage tumorigenesis pathway: a potentially general technique for isolating physiologically representative cell lines. Mol. Cell. Biol., 13: 4223-4232, 1993.
29. Baker, A., Saltik, M., Lehrmann, H., Killisch, I., Mautner, V., Lamm, G., Christofori, G., and Cotten, M. Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery. Gene Therapy, 4: 773-782, 1997.
30. Lamm, G. M., Steinlein, P., Cotten, M., and Christofori, G. A rapid, quantitative and inexpensive method for detecting apoptosis by flow cytometry in transiently transfected cells. Nucleic Acid Res., 25: 4855-4857, 1997.
31. Tamaoki, T., and Nakano, H. Potent and specific inhibitors of protein kinase C of microbial origin. BioTechnology, 8: 732-735, 1990.
32. Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y., and Jacobson, M. D. Programmed cell death and the control of cell survival: lessons from the nervous system. Science (Washington DC), 262: 695-700, 1993.
33. Jacobsen, M. D., Weil, M., and Raff, M. C. Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death. J. Cell Biol., 133: 1041-1051, 1996.
34. Kamesaki, S., Kamesaki, H., Jorgensen, T. J., Tanizawa, A., Pommier, Y., and Cossman, J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res., 53: 4251-4256, 1993.
35. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 54: 665-697, 1985.
36. Slewart, C. F., and Ratain, M. J. Topoisomerase interactive agents. In: J. DeVita, S. Hellman, and S. A. Rosenberg (eds.). Cancer: Principles and Practice of Oncology, Vol. 1, pp. 452-467. New York: Lippincott-Raven Publishers, 1997.
37. Rowinsky, E. K., and Donehower, R. C. Antimicrotubule agents. In: J. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Vol. 1, pp. 467-483. New York: Lippincott-Raven Publishers, 1997.
38. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
39. Yee, D., Paik, S., Lebovic, G. S., Marcus, R. R., Favoni, R. E., Cullen, K. J., Lippman, M. E., and Rosen, N. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol. Endocrinol., 3: 509-514, 1989.
40. Cullen, K. I., Yee, D., Sly, W. S., Perdue, J., Hampton, B., Lippman, M. E., and Rosen, N. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res., 49: 7002-7009, 1990.
41. Kaiser, U., Schardt, C., Brandscheidt, D., Wollmer, E., and Havemann, K. Expression of insulin-like growth factor receptors I and II in normal lung and in lung cancer. J. Cancer Res. Clin. Oncol., 119: 665-668, 1993.
42. Remaole-Bennet, M. M., Culouscou, J. M., Garrouste, F. L., Rabenandrasana, C., Marvaldi, J. L., and Pommier, G. J. Expression of type I, but not type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell lines. J. Clin. Endocrinol. Metab., 75: 609-616, 1992.
43. Reeve, A. E., Eccles, M. R., Wilkins, R. J., Bell, G. I., and Millow, L. J. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature (Lond.), 317: 258-260, 1985.
44. Scott, J., Cowell, J., Robertson, M. E., Priestley, L. M., Wadey, R., Hopkins, B., Pritchard, J., Bell, G. I., Rall, L. B., and Graham, C. F. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature (Lond.), 317: 260-262, 1985.
45. Resnicoff, M., Coppola, D., Sell, C., Rubin, R., Ferrone, S., and Baserga, R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res., 54: 4848-4850, 1994.
46. Resnicoff, M., Sell, C., Rubini, M., Coppola, D., Ambrose, D., Baserga, R., and Rubin, R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res., 54: 2218-2222, 1994.
47. Conover, C. A., Misra, P., Hintz, R. L., and Rosenfeld, R. G. Effect of an anti-insulin-like growth factor I receptor antibody on insulin-like growth factor II stimulation in human fibroblasts. Biochem. Biophys. Res. Commun., 139: 501-508, 1986.
48. Papa, V., Hartmann, K. K., Rosenthal, S. M., Maddux, B. A., Siiteri, P. K., and Goldfine, I. D. Progestins induce downregulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: potential autocrine role of IGF-II. Mol. Endocrinol., 5: 709-717, 1991.
49. Porcu, P., Ferber, A., Pietrzkowski, Z., Roberts, C. T., Adamo, M., LeRoith, D., and Baserga, R. The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulin like growth factor 1 with its receptor. Mol. Cell. Biol., 11: 5069-5077, 1992.
50. Thompson, M. A., Cox, A. J., Whitehead, R. H., and Jonas, H. A. Autocrine regulation of human tumor cell proliferation by insulin-like growth factor II: an in vitro model. Endocrinology, 6: 3033-3042, 1990.
51. Steller, M. A., Zou, Z., Schiller, J. T., and Baserga, R. Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor. Cancer Res., 56: 5087-5091, 1996.
52. Steller, M. A., Delgado, C. H., Bartels, C. J., Woodworth, C. D., and Zou, Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res., 56: 1761-1765, 1996.
53. Sell, C., Rubini, M., Rubin, R., Liu, J. P., Efstratiadis, A., and Baserga, R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA, 90: 11217-11221, 1993.
54. O'Connor, R., Kauffmann-Zeh, A., Liu, Y., Lehar, S., Evan, G. I., Baserga, R., and Blättler, W. A. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell. Biol., 17: 427-435, 1997.
55. Kauffmann-Zeh, A., Rodriquez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Down-ward, J., and Evan, G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature (Lond.), 385: 544-548, 1997.
56. Yao, R., and Cooper, G. M. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science (Washington DC), 267: 2003-2006, 1995.
57. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, N. P. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 81: 727-736, 1995.
58. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (Washington DC), 275: 661-665, 1997.
59. Chresta, C. M., Masters, J. R., and Hickman, J. A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res., 56: 1834-1841, 1996.
60. Sumantran, V. N., Ealovega, M. W., Nunez, G., Clarke, M. F., and Wicha, M. S. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res., 55: 2507-2510, 1995.
61. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
62. Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Nunez, G., and Castle, V. P. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55: 2576-2582, 1995.
63. Eliopoulos, A. G., Kerr, D. J., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C., and Young, L. S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11: 1217-1228, 1995
64. Tu, Y., Xu, F. H., Liu, J., Vescio, R., Berenson, J., Fady, C., and Lichtenstein, A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood, 88: 1805-1812, 1996.
65. Naik, P., Karrim, J., and Hanahan, D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev., 10: 2105-2116, 1996.
66. Ko, L. J., and Prives, C. p53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.
67. Berges, R. R., Furaya, Y., Remington, L., English, H. F., Jacks, T., and Isaacs, J. T. Cell proliferation, DNA repair, and p53 function are not required for programmed cell death of prostatic gladular cells induced by androgen ablation. Proc. Natl. Acad. Sci. USA, 90: 8910-8914, 1993.
68. Strasser, A., Harris, A. W., Jacks, T., and Cory, S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 79: 329-339, 1994.